Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
Abdominal NeoplasmsPelvic Neoplasms
Interventions
DRUG

Optison

"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00186953 - Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors | Biotech Hunter | Biotech Hunter